Paper Details

  1. Home
  2. Paper Details

Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria: A Systematic Review.

Author: PoletajewSławomir, RadziszewskiPiotr, ZapałaPiotr

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This systematic review examines the safety and efficacy of intravesical Bacillus Calmette-Guérin (BCG) immunotherapy in bladder cancer patients with asymptomatic bacteriuria (ABU). The findings suggest that BCG instillations in patients with ABU do not increase the risk of symptomatic urinary tract infections and do not negatively impact recurrence-free or progression-free survival. The review concludes that routine urine analysis before BCG instillation is not necessary.
Paper Details　
Original Abstract of the Article :
Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy in bladder cancer patients with asymptomatic bacteriuria (ABU) remains a matter of debate. The aim of this systematic review was to present available evidence on the safety and efficacy of BCG immunotherapy in patients with ABU. A literature ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1159/000477673

データ提供：米国国立医学図書館（NLM）

Bacillus Calmette-Guérin (BCG) Immunotherapy: A Safe and Effective Treatment for Bladder Cancer

Bladder cancer, a common malignancy, often requires intravesical BCG immunotherapy for treatment. This study examines the safety and efficacy of BCG immunotherapy in patients with asymptomatic bacteriuria (ABU), a condition that can complicate the treatment process. The research provides valuable insights into the management of ABU in bladder cancer patients undergoing BCG immunotherapy.

Addressing Asymptomatic Bacteriuria in Bladder Cancer Treatment

The study concludes that ABU does not significantly affect the safety or efficacy of intravesical BCG immunotherapy. The research also suggests that routine urine analysis before BCG instillation might be unnecessary and potentially delays the treatment process.

Navigating the Sands of Bladder Cancer Treatment

This study underscores the importance of carefully considering the potential impact of ABU on BCG immunotherapy. The findings suggest that routine screening and treatment of ABU might not be necessary in all patients, allowing for a more streamlined treatment approach.

Dr.Camel's Conclusion

This research provides valuable guidance for managing bladder cancer patients with ABU. The findings suggest that ABU does not compromise the efficacy of BCG immunotherapy and that routine screening and treatment might be unnecessary.
Date :
  1. Date Completed 2018-05-07
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

28601885

DOI: Digital Object Identifier

10.1159/000477673

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.